CTSE抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse stomach tissue, Primary antibody: P07163(CTSE Antibody) at dilution 1/525, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P07163(CTSE Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07163(CTSE Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of CTSE Antibody**

Cathepsin E (CTSE), a member of the aspartic protease family, is an intracellular protease primarily expressed in immune cells, such as macrophages, dendritic cells, and B lymphocytes. Unlike other cathepsins, CTSE is localized in endosomes and lysosomes, playing roles in antigen processing, protein degradation, and immune regulation. Its expression is tightly regulated and often linked to inflammatory and immune responses.

CTSE has garnered attention due to its association with various diseases. Overexpression or dysregulation of CTSE is observed in cancers (e.g., gastric, colorectal), inflammatory disorders (e.g., rheumatoid arthritis), and autoimmune conditions, suggesting its potential as a therapeutic target or diagnostic marker. Antibodies targeting CTSE are critical tools for studying its function, expression patterns, and involvement in disease mechanisms.

CTSE-specific antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to detect protein levels and localization in tissues or cell lines. They also aid in functional studies, such as blocking CTSE activity to explore its role in pathological processes. Commercial CTSE antibodies are developed by multiple biotech companies, often validated for specificity and sensitivity in diverse applications. Ongoing research aims to refine antibody-based therapies, such as CTSE-targeted immunoconjugates, to enhance precision in treating CTSE-associated diseases.